Spotlight
Video

EHA 2015: Phase 2 study of daratumumab monotherapy for heavily pretreated and refractory multiple myeloma

VJHemOnc has 1608 videos Subscribe Here

Loading........
Description: At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, evaluates the results of a phase 2 study of monotherapy with the anti-CD38 monoclonal antibody, daratumumab, for patients with multiple myeloma who have received at least three different lines of therapy or who are double refractory.

—————

The Video Journal of Hematological Oncology (VJHemOnc) is an independent, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve understanding and awareness of hematological malignancies.

Website: http://www.vjhemonc.com/...
Twitter: https://twitter.com/VJHemOn...
Facebook: https://www.facebook.com/vj...
LinkedIn: https://www.linkedin.com/co...
Shared By : VJHemOnc
Posted on : 08/18/15
Added : 4 years ago
Category : Multiple Myeloma